Bone News and Research

RSS

Researchers identify 56 genetic variants that influence BMD

Researchers at The Institute for Aging Research at Hebrew SeniorLife, an affiliate of Harvard Medical School, have co-authored the largest meta-analysis of genome-wide association studies of osteoporosis as part of an international consortium and have identified dozens of genetic variants found to be linked to an increased risk of developing osteoporosis and of suffering broken bones.

17 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

32 genetic variations could play a role in osteoporosis risk

A team of international researchers have found 32 new genetic regions linked to fractures and osteoporosis. According to the new study published in the April 15 online edition of Nature Genetics, changes in these regions could offer protection from, or greater risk for, bone-weakening disease.

16 Apr 2012

NTD experts push forward on plan to eradicate yaws

Yaws, a skin and bone disease caused by a treponematoses bacterium that can cause long-term deformities, "has recently been put on WHO's list of 17 so-called neglected tropical diseases (NTDs)" and, along with Guinea worm, is "slated for eradication," the Lancet reports.

16 Apr 2012

$Researchers identify 32 genetic regions associated with osteoporosis, fracture$

Researchers identify 32 genetic regions associated with osteoporosis, fracture

Thirty-two previously unidentified genetic regions associated with osteoporosis and fracture have been identified by a large, worldwide consortium of researchers, including Stanford Prevention Research Center chief John Ioannidis, MD, DSc. Variations in the DNA sequences in these regions confer either risk or protection from the bone-weakening disease. Many, but not all, of the regions encode proteins involved in pathways known to involve bone health.

16 Apr 2012

The key to treating AML may lie within FTL3 gene mutations

The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.

16 Apr 2012

Study reveals genetic predictors of bone health and osteoporosis

An international consortium of researchers have identified a group of genes associated with the development of osteoporosis, a debilitating bone disease that cripples more than 10 million Americans a year and costs the U.S. healthcare system an estimated $17 billion annually.

16 Apr 2012

ALL induction treatment failure should not be an automatic indication for bone marrow transplant

International study that included St. Jude Children's Research Hospital reports some young acute lymphoblastic leukemia patients who fail induction therapy can achieve high cure rates without bone marrow transplantation.

12 Apr 2012

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

New research from The Ohio State University utilizes two different methods to visualize circulating tumor cells (CTCs) as well as other unusual circulating cells with both epithelial and hematopoietic characteristics in metastatic breast cancer.

12 Apr 2012

Study: Stem cells from pelvic bone marrow may help hearts beat stronger

Stem cells from the pelvic bone may help hearts beat stronger. Doctors and other clinicians at the Orlando Health Heart Institute are researching the use of stem cells from pelvic bone marrow to restore tissue and improve heart function after muscle damage from heart attacks.

12 Apr 2012

Biomet third quarter net sales increase 5% to $708.9 million

Biomet, Inc. announced today financial results for its third fiscal quarter ended February 29, 2012.

12 Apr 2012

Vilex announces commercial launch of FUZE TTC Arthrodesis Compression Nail

Vilex Inc., a leader in innovative orthopaedic medical devices announced the commercial launch of the FUZE TTC Arthrodesis Compression Nail, the most recent addition to the Vilex line.

11 Apr 2012

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.

11 Apr 2012

NYU Langone announces opening of Center for Musculoskeletal Care

NYU Langone Medical Center ushered in the next generation of orthopaedic, rheumatologic and rehabilitative care with the opening of the Center for Musculoskeletal Care (CMC) at 333 East 38th Street in Manhattan last week.

11 Apr 2012

Top ten facts about organ and tissue donation

Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.

10 Apr 2012

More than 60% of breast cancer survivors report post-treatment complications

More than 60 percent of breast cancer survivors report at least one treatment-related complication even six years after their diagnosis, according to a new study led by a researcher from the Perelman School of Medicine at the University of Pennsylvania.

10 Apr 2012

Study examines potential impact of policies to reduce inappropriate imaging for prostate cancer

In the current hyper-charged United States healthcare debate, the focus on lowering cost without compromising quality of care remains a priority. But according to a new study by researchers at NYU Langone Medical Center and colleagues, one common approach may have serious unintended consequences.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

Med-Tek introduces proprietary Opioid Management Program

Med-Tek a developer of Healthcare Technology Networks ("HTN") designed to improve outcomes for patients, physicians, employers and their constituents today announces the launch of its proprietary Opioid Management Program (OMP).

9 Apr 2012

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

9 Apr 2012